½ÃÀ庸°í¼­
»óǰÄÚµå
1741112

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå : À¯Çüº°, Á¦Ç°º°, Áö¿ªº°

Digital Diabetes Management Market, By Type and By Product, and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀº 2025³â¿¡ 139¾ï 7,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â±îÁö 578¾ï 3,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁöÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 22.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁØ ¿¬µµ 2024³â ½ÃÀå ±Ô¸ð(2025³â) 139¾ï 7,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR : 22.50% °¡Ä¡ ¿¹Ãø(2032³â) 578¾ï 3,000¸¸ ´Þ·¯

½º¸¶Æ® Àν¶¸° Ææ, ½º¸¶Æ® Àν¶¸° ÆßÇÁ, ½º¸¶Æ® Æ÷µµ´ç ¹ÌÅÍ, ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ÀåÄ¡¿Í °°Àº µðÁöÅÐ ´ç´¢º´ °ü¸® ÀåÄ¡´Â ´ç´¢º´ ȯÀÚ(iÇü ¹× IIÇü)ÀÇ Æ÷µµ´ç ¼öÁØ Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±â¼úÀûÀ¸·Î °íµµÀÇ ´ç´¢º´ °ü¸® ±â±â(µðÁöÅÐ ´ç´¢º´ °ü¸® ±â±â) ¼ö¿äµµ ±Þ¼ÓÇÑ ¼Óµµ·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

´ç´¢º´ ºÎ´ã Áõ°¡, ³ë³â Àα¸ Áõ°¡, ´ç´¢º´ °ü¸® Àåºñ¿¡ ÀΰøÁö´É(AI) µµÀÔ, µðÁöÅÐ ´ç´¢º´ °ü¸® Àåºñ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ´ç´¢º´ °ü¸® ¹× ±â¼úÀûÀ¸·Î °í±Þ ´ç´¢º´ °ü¸® ÀåºñÀÇ ÀåÁ¡¿¡ ´ëÇÑ »ç¶÷µéÀÇ ÀÇ½Ä Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

¿¹¸¦ µé¾î, 2022³â 11¿ù, À϶óÀÌ ¸±¸® ¾Ø ÄÄÆÛ´Ï(LLY)´Â ¹Ì±¹¿¡¼­ ÃÖÃÊÀÇ Ä¿³ØÆ¼µå Ç÷§ÆûÀÎ ÅÛÆ÷ ¸ÂÃãÇü ´ç´¢º´ °ü¸® Ç÷§ÆûÀ» Ãâ½ÃÇÒ °èȹÀ̾ú½À´Ï´Ù. ÀÌ Ç÷§ÆûÀº 1Çü ¶Ç´Â 2Çü ´ç´¢º´ ȯÀÚ ¹× ÀÓ»óÀǰ¡ ¸±¸®ÀÇ Àν¶¸° Ä¡·á¸¦ °ü¸®Çϱâ À§ÇØ Á¤º¸¸¦ ±â¹ÝÀ¸·Î µ¥ÀÌÅÍ¿¡ µÞ¹ÞħµÇ´Â ÀÇ»ç°áÁ¤À» ¼öÇàÇÏ´Â µ¥ µµ¿òÀ» ÁÖ±â À§ÇÑ °ÍÀÔ´Ï´Ù.

¶ÇÇÑ 2022³â 3¿ù Àεµ ¸ÞµåÆ®·Î´ÐÀº Àεµ¿¡¼­ ¹Ì´Ï¸Þµå 780G ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£ 2025-2032³â ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
  • ¶Ç, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÇô, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ¼­ ÇØ¼³Çß½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° ¹ß¸Å ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µî ¾Æ·¡ÀÇ ÆÄ¶ó¹ÌÅ͸¦ ¹ÙÅÁÀ¸·Î ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
  • º» º¸°í¼­·ÎºÎÅÍÀÇ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ³ª ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±Ù°ÅÇÑ ÀÇ»ç °áÁ¤À» ½Ç½ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±ÞÀÚ, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ¾Ö³Î¸®½ºÆ® µî, ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ °ü°èÀÚ¸¦ ´ë»óÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇØÁý´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüµÈ ±âȸ ¸Ê(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼¼°è¿¡¼­ ´ç´¢º´ÀÇ ÀÌȯÀ²ÀÌ Áõ°¡
    • µðÁöÅÐ ´ç´¢º´ °ü¸® ÀåÄ¡ÀÇ °íºñ¿ë
    • µðÁöÅÐ °ü¸® µð¹ÙÀ̽º ¼ö¿ä Áõ°¡
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTER ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå µðÁöÅÐ ´ç´¢º´ °ü¸® ¸¶½ºÅ© ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) À¯ÇàÀÇ ¿µÇâ

  • COVID-19 ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃøÀÇ ºÐ¼®
  • °æÁ¦¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦5Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, À¯Çüº°(2020-2032³â)

  • ÇÚµåÇïµå µð¹ÙÀ̽º
  • ¿þ¾î·¯ºí µð¹ÙÀ̽º

Á¦6Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, Á¦Ç°º°(2020-2032³â)

  • ¿¬¼Ó Ç÷´ç ¸ð´ÏÅ͸µ ½Ã½ºÅÛ
  • ½º¸¶Æ® Ç÷´ç ÃøÁ¤±â
  • ½º¸¶Æ® Àν¶¸° ÆßÇÁ
  • ½º¸¶Æ® Àν¶¸° Ææ
  • ¾Û

Á¦7Àå ¼¼°èÀÇ µðÁöÅÐ ´ç´¢º´ °ü¸® ½ÃÀå, Áö¿ªº°(2020-2032³â)

  • ºÏ¹Ì
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • Abbott Laboratories
  • Acon Laboratories, Inc.
  • Bayer AG
  • F. Hoffmann-la Roche Ltd.
  • Johnson and Johnson
  • Medtronic Plc
  • Novo Nordisk A/S
  • Terumo Corporation
  • Dexcom, Inc.
  • Becton, Dickinson and Company

Á¦9Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
KTH

Digital Diabetes Management Market is estimated to be valued at USD 13.97 Bn in 2025 and is expected to reach USD 57.83 Bn by 2032, growing at a compound annual growth rate (CAGR) of 22.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 13.97 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 22.50% 2032 Value Projection: USD 57.83 Bn

Digital diabetes management devices, like smart insulin pens, smart insulin pumps, smart glucose meter, and continuous blood glucose monitoring devices, help people with diabetes (type I and II) to monitor and manage their glucose levels. Thus, with the increasing prevalence of diabetes across the globe, the demand for technologically advanced diabetes management devices (digital diabetes management devices) is also increasing with a rapid pace.

Market Dynamics:

Rise in burden of diabetes, growing geriatric population, introduction of artificial intelligence (AI) in diabetes management devices, increasing demand for digital diabetes management devices, and increasing awareness among people about diabetes care and benefits of technologically advanced diabetes management devices are major factors expected to propel the growth of the global digital diabetes management market over the forecast period.

For instance, in November 2022, Eli Lilly and Company (LLY) planned to rollout first connected platform, the Tempo Personalized Diabetes Management Platform, in the U.S. The platform aims to help individuals living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins.

Moreover, in March 2022, India Medtronic Private Limited announced the launch of the MiniMed 780G system in India. The MiniMed 780G system is a next generation closed loop insulin pump system for the treatment of type 1 diabetes in people age 7 to 80 years.

Key features of the study:

  • This report provides in-depth analysis of the global digital diabetes management market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global digital diabetes management market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Abbott Laboratories, Acon Laboratories, Inc., Bayer AG, F. Hoffmann-la Roche Ltd., Johnson and Johnson, Medtronic Plc, Novo Nordisk A/S, Terumo Corporation, Dexcom, Inc., and Becton, Dickinson and Company, among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global digital diabetes management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global digital diabetes management market.

Detailed Segmentation:

  • Global Digital Diabetes Management Market, By Type:
    • Handheld Devices
    • Wearable Devices
  • Global Digital Diabetes Management Market, By Product:
    • Continuous Blood Glucose Monitoring Systems
    • Smart Glucose Meter
    • Smart Insulin Pumps
    • Smart Insulin Pens
    • Apps
  • Global Digital Diabetes Management Market, By Geography:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Abbott Laboratories
    • Acon Laboratories, Inc.
    • Bayer AG
    • F. Hoffmann-la Roche Ltd.
    • Johnson and Johnson
    • Medtronic Plc
    • Novo Nordisk A/S
    • Terumo Corporation
    • Dexcom, Inc.
    • Becton, Dickinson and Company

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Product
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing prevalence of diabetes around the world
    • High cost of digital diabetes management devices
    • Increasing demand for digital management devices
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Digital Diabetes Management Mask Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Digital Diabetes Management Market, By Type, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Handheld Devices
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Wearable Devices
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Digital Diabetes Management Market, By Product, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Continuous Blood Glucose Monitoring Systems
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Smart Glucose Meter
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Smart Insulin Pumps
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Smart Insulin Pens
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
  • Apps
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Digital Diabetes Management Market, By Region, 2020-2032, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2020-2032,(US$ Bn)

8. Competitive Landscape

  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Acon Laboratories, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • F. Hoffmann-la Roche Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Johnson and Johnson
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Medtronic Plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novo Nordisk A/S
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Terumo Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dexcom, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton, Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦